| IPO Company Profile © ipodata.com |
| Message Board | Quote | Chart | News | SEC Filings | Peer IPO Companies |
| Discovery Partners International, Inc. |
| 9640 Towne Centre Drive, San Diego, CA 92121 * (858) 455-8600 |
| Business Description | The company sells a broad range of products and services to pharmaceutical and biotechnology companies to make the drug discovery process for customers faster, less expensive and more effective at generating drug candidates. |
| Offering Information Company has | |||
| Trading As | DPII (NASNTL) | Industry | Service (SIC 8731) |
| Type of Stock Offered | Common Shares | Filing Date | 5/9/00 |
| Domestic Shares Offered | 5,000,000 | Offer Date | 7/26/00 |
| Foreign Shares Offered | 0 | Filing Range | $15.00 - $17.00 |
| Company Shares | 5,000,000 | Offer Price | $18.00 |
| Selling Shrhldrs Shares | 0 | Gross Spread | $1.260 |
| Gross Proceeds | $90,000,000 | Selling | $0.750 |
| Expenses | - - | Reallowance | $0.100 |
| Post-IPO Shares | 22,400,000 | Employees | - - |
| Primary Underwriting Group | ||
| Underwriter Name | Participation | Underwriter Phone |
| Chase H&Q; | Lead Manager | (415) 439-3626 |
| Lehman Brothers Incorporated | Co-manager | (212) 526-8100 |
| UBS Warburg LLC | Co-manager |
| Income Statement and Cash Flow Summary | |||||||
| Prior Audited Income |
Latest Unaudited Income | ||||||
| Full Year Audited Figures | 3 Months Ending | ||||||
| Figures in U.S. millions except per share data | 12/31/97 | 12/31/98 | 12/31/99 | 3/31/99 | 3/31/00 | ||
| Revenues | - | - | 3.150 | 6.214 | 13.076 | 2.896 | 5.173 |
| Income from Oper. | - | - | -4.833 | -6.614 | -3.447 | -0.999 | -0.437 |
| Net Income | - | - | -4.822 | -6.278 | -3.370 | -0.973 | -1.630 |
| E.P.S | - | - | -8.850 | -8.200 | -3.000 | -0.960 | -1.230 |
| Revenue Growth (%) | - | - | 97.27 | 110.428 | 78.63 | ||
| Net Income Growth (%) | - | - | - | - | - | ||
| Oper. Profit Margin (%) | - | - | - | - | - | - | - |
| Net Profit Margin (%) | - | - | - | - | - | - | - |
| Cash Flow - Oper. | -5.74 | -2.23 | -1.28 | ||||
| Cash Flow - Inv. | -5.89 | -0.02 | -2.97 | ||||
| Cash Flow - Fin. | 3.80 | -0.06 | 2.50 | ||||
| Balance Sheet Summary and Financial Ratios | |||||
| Balance sheet as of: 3/31/00 | Financial Ratios | ||||
| Total Assets | 21.75 | Current Assets | 6.89 | Current Ratio | 0.64 |
| Total Liab. | 41.31 | Current Liab. | 10.84 | Debt Ratio | 189.94% |
| Total Equity | -19.56 | Working Cap. | -3.95 | Debt to Equity Ratio | - |
| Cash | 0.98 | Return on Assets | - | ||
| Use Of Proceeds |
The proceeds from the proposed offering will be used for to fund operations, including continued development and manufacturing of existing products as well as research and development of additional products and services, general corporate purposes. |
| Legal Counsel Registrar Auditor | |
| Issuer's Law Firm | Brobeck, Phleger & Harrison |
| Bank's Law Firm | Cooley Godward Castro Huddleson & Tatum |
| Registrar/Transfer Agent | American Stock Transfer & Trust Co |
| Auditor | Ernst & Young |
| Send us feedback if you would like to request that we hyperlink a firm on this page | |
| Principal Shareholders | ||
| Name of Shareholder | % Owned Before | % Owned After |
| Axys Pharmaceuticals, Inc. | 43.20 | |
| Enterprise Partners affiliated entities | 13.40 | |
| Mayfield Fund affiliated entities | 13.00 | |
| Crosspoint affiliated entities | 10.80 | |
| Note: represents ownership of 5% or more prior to the offering. | ||